Aziyo Biologics, Inc. (AZYO) reported Q3 EPS of ($0.73), $0.06 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $5.05 million versus the consensus estimate of $12.38 million.
GUIDANCE:
Aziyo Biologics, Inc. sees FY2022 revenue of $48-50 million.